Companies
WHO Warning On 'Single Drug' Malaria Therapies
January 2006 | Company Finance AlertThe World Health Organisation (WHO) has called on a number of drug firms in the world to stop selling artemisinin-based, "single drug" malaria treatments to Africa, amid concerns that efficacy levels are falling. The use of artemisinin weakens the parasite that causes malaria but does not kill it, potentially allowing resistance to develop.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.



